Epigenetic-based immune intervention for rheumatic diseases

Epigenomics

Volumn 6, Issue 2, 2014, Pages 253-271

  Gray, Steven G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

autoimmunity; bioactive compounds; clinical trials; DNA methylation; epigenetics; histone post translational modifications; miRNA; rheumatic disease

Indexed keywords

HISTONE; METHYL CPG BINDING PROTEIN 2; UNTRANSLATED RNA;

AUTOIMMUNITY; CONNECTIVE TISSUE; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE TARGETING; HISTONE MODIFICATION; HUMAN; IMMUNOREACTIVITY; IMMUNOTHERAPY; JOINT; LONG TERM CARE; MUSCLE; MUSCULOSKELETAL SYSTEM; NONHUMAN; NUTRITION; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SOFT TISSUE; SYSTEMIC LUPUS ERYTHEMATOSUS; CD4+ T LYMPHOCYTE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; RHEUMATIC DISEASES;

AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RHEUMATIC DISEASES;

EID: 84900429337     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.13.87     Document Type: Review

References (179)

1. American College of Rheumatology.www.rheumatology.org
2. Park SH, Kim SK, Choe JY et al. Hypermethylation of EBF3 and IRX1 genes in synovial fibroblasts of patients with rheumatoid arthritis. Mol. Cells 35(4), 298-304 (2013).
3. Sandoval J, Esteller M. Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 22(1), 50-55 (2012).
4. Gray SG, De Meyts P. Role of histone and transcription factor acetylation in diabetes pathogenesis. Diabetes Metab. Res. Rev. 21(5), 416-433 (2005). (Pubitemid 41320653)
5. Gray SG. Epigenetic treatment of neurological disease. Epigenomics 3(4), 431-450 (2011).
6. Silman AJ, Macgregor AJ, Thomson W et al. Twin concordance rates for rheumatoid arthritis. results from a nationwide study. Br. J. Rheumatol. 32(10), 903-907 (1993). (Pubitemid 23301303)
7. Jarvinen P, Aho K. Twin studies in rheumatic diseases. Semin. Arthritis Rheum. 24(1), 19-28 (1994). (Pubitemid 24258758)
8. Macgregor AJ, Snieder H, Rigby AS et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43(1), 30-37 (2000). (Pubitemid 30368210)
9. Svendsen AJ, Kyvik KO, Houen G et al. On the origin of rheumatoid arthritis. The impact of environment and genes-a population based twin study. PLoS ONE 8(2), e57304 (2013).
10. Connolly JJ, Hakonarson H. Role of cytokines in systemic lupus erythematosus: recent progress from GWAS and sequencing. J. Biomed. Biotechnol. 798-924 (2012).
11. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895), 89-92 (1983). (Pubitemid 13154475)
12. Ellis JA, Munro JE, Chavez RA et al. Genome-scale case-control analysis of CD4+ T-cell DNA methylation in juvenile idiopathic arthritis reveals potential targets involved in disease. Clin. Epigenetics 4(1), 20 (2012).
13. Patel DR, Richardson BC. Dissecting complex epigenetic alterations in human lupus. Arthritis Res. Ther. 15(1), 201 (2013).
14. A look at the origins of cancer epigenetics. Cancer Discov. 3(7), 713 (2013).
15. Baylin SB, Jones PA. Epigenetic determinants of cancer. In: Epigenetics. Allis CD, Jenuwein T, Reinberg D (Eds). Cold Spring Harbor Press, NY, USA, 457-476 (2006).
16. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33(11), 1665-1673 (1990).
17. Javierre BM, Fernandez AF, Richter J et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 20(2), 170-179 (2010).
18. Jeffries MA, Dozmorov M, Tang Y, Merrill JT, Wren JD, Sawalha AH. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics 6(5), 593-601 (2011).
19. Absher DM, Li X, Waite LL et al. Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations. PLoS Genet. 9(8), e1003678 (2013).
20. Coit P, Jeffries M, Altorok N et al. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naive CD4+ T cells from lupus patients. J. Autoimmun. 43, 78-84 (2013).
21. Lin SY, Hsieh SC, Lin YC et al. A whole genome methylation analysis of systemic lupus erythematosus. hypomethylation of the IL10 and IL1R2 promoters is associated with disease activity. Genes Immun. 13(3), 214-220 (2012).
22. Zhu X, Liang J, Li F, Yang Y, Xiang L, Xu J. Analysis of associations between the patterns of global DNA hypomethylation and expression of DNA methyltransferase in patients with systemic lupus erythematosus. Int. J. Dermatol. 50(6), 697-704 (2011).
23. Lei W, Luo Y, Yan K et al. Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand. J. Rheumatol. 38(5), 369-374 (2009).
24. Liu Y, Aryee MJ, Padyukov L et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis. Nat. Biotechnol. 31(2), 142-147 (2013).
25. Nakano K, Whitaker JW, Boyle DL, Wang W, Firestein GS. DNA methylome signature in rheumatoid arthritis. Ann. Rheum. Dis. 72(1), 110-117 (2013).
26. Nakano K, Boyle DL, Firestein GS. Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J. Immunol. 190(3), 1297-1303 (2013).
27. Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat. Rev. Rheumatol. 9(1), 24-33 (2013).
28. Whitaker JW, Shoemaker R, Boyle DL et al. An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotype. Genome Med. 5(4), 40 (2013).
29. Koelsch KA, Webb R, Jeffries M et al. Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse. J. Autoimmun. 41, 168-174 (2013).
30. Han TU, Cho SK, Kim T, Joo YB, Bae SC, Kang C. Association of an activity-enhancing variant of IRAK1 and an MECP2-IRAK1 haplotype with increased susceptibility to rheumatoid arthritis. Arthritis Rheum. 65(3), 590-598 (2013).
31. Miao CG, Huang C, Huang Y et al. MeCP2 modulates the canonical Wnt pathway activation by targeting SFRP4 in rheumatoid arthritis fibroblast-like synoviocytes in rats. Cell. Signal. 25(3), 598-608 (2013).
32. Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502(7472), 472-479 (2013).
33. Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat. Rev. Mol. Cell Biol. 14(6), 341-356 (2013).
34. Zhang Y, Zhao M, Sawalha AH, Richardson B, Lu Q. Impaired DNA methylation and its mechanisms in CD4+ T cells of systemic lupus erythematosus. J. Autoimmun. 41, 92-99 (2013).
35. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 140(7), 2197-2200 (1988). (Pubitemid 18098475)
36. Richardson BC, Strahler JR, Pivirotto TS et al. Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum. 35(6), 647-662 (1992).
37. Yung RL, Quddus J, Chrisp CE, Johnson KJ, Richardson BC. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J. Immunol. 154(6), 3025-3035 (1995).
38. Minguez P, Letunic I, Parca L, Bork P. PTMcode: a database of known and predicted functional associations between post-translational modifications in proteins. Nucleic Acids Res. 41(D1), D306-D311 (2013).
39. Minguez P, Parca L, Diella F et al. Deciphering a global network of functionally associated post-translational modifications. Mol. Syst. Biol. 8, 599 (2012).
40. Gay S, Wilson AG. The emerging role of epigenetics in rheumatic diseases. Rheumatology (Oxford) 53(3), 406-414 (2014).
41. Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J. Rheumatol. 36(8), 1580-1589 (2009).
42. Gillespie J, Savic S, Wong C et al. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Rheum. 64(2), 418-422 (2012).
43. Kawabata T, Nishida K, Takasugi K et al. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res. Ther. 12(4), R133 (2010).
44. Huber LC, Brock M, Hemmatazad H et al. Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients. Arthritis Rheum. 56(4), 1087-1093 (2007). (Pubitemid 46608633)
45. Kirsh O, Seeler JS, Pichler A et al. The SUMO E3 ligase RanBP2 promotes modification of the HDAC4 deacetylase. EMBO J. 21(11), 2682-2691 (2002). (Pubitemid 34619384)
46. Gregoire S, Tremblay AM, Xiao L et al. Control of MEF2 transcriptional activity by coordinated phosphorylation and sumoylation. J. Biol. Chem. 281(7), 4423-4433 (2006). (Pubitemid 43847874)
47. Wang WL, Lee YC, Yang WM, Chang WC, Wang JM. Sumoylation of LAP1 is involved in the HDAC4-mediated repression of COX-2 transcription. Nucleic Acids Res. 36(19), 6066-6079 (2008).
48. Yang Y, Tse AK, Li P et al. Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation. Oncogene 30(19), 2207-2218 (2011).
49. Chabane N, Li X, Fahmi H. HDAC4 contributes to IL-1-induced mPGES-1 expression in human synovial fibroblasts through up-regulation of Egr-1 transcriptional activity. J. Cell. Biochem. 106(3), 453-463 (2009).
50. Maciejewska-Rodrigues H, Karouzakis E, Strietholt S et al. Epigenetics and rheumatoid arthritis. The role of SENP1 in the regulation of MMP-1 expression. J. Autoimmun. 35(1), 15-22 (2010).
51. Trenkmann M, Brock M, Gay RE et al. Expression and function of EZH2 in synovial fibroblasts. epigenetic repression of the Wnt inhibitor SFRP1 in rheumatoid arthritis. Ann. Rheum. Dis. 70(8), 1482-1488 (2011).
52. Levy D, Kuo AJ, Chang Y et al. Lysine methylation of the NF-kappaB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-kappaB signaling. Nat. Immunol. 12(1), 29-36 (2011).
53. Yan K, Cao Q, Reilly CM, Young NL, Garcia BA, Mishra N. Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity. J. Biol. Chem. 286(33), 28833-28843 (2011).
54. Hu N, Qiu X, Luo Y et al. Abnormal histone modification patterns in lupus CD4+ T cells. J. Rheumatol. 35(5), 804-810 (2008). (Pubitemid 351747120)
55. Lashine YA, Seoudi AM, Salah S, Abdelaziz AI. Expression signature of microRNA-181-a reveals its crucial role in the pathogenesis of paediatric systemic lupus erythematosus. Clin. Exp. Rheumatol. 29(2), 351-357 (2011).
56. Zhang Q, Long H, Liao J et al. Inhibited expression of hematopoietic progenitor kinase 1 associated with loss of jumonji domain containing 3 promoter binding contributes to autoimmunity in systemic lupus erythematosus. J. Autoimmun. 37(3), 180-189 (2011).
57. Zhao M, Sun Y, Gao F et al. Epigenetics and SLE. RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells. J. Autoimmun. 35(1), 58-69 (2010).
58. Zhao M, Wu X, Zhang Q et al. RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1. Arthritis Res. Ther. 12(6), R227 (2010).
59. Glant TT, Besenyei T, Kadar A et al. Differentially expressed epigenome modifiers, including aurora kinases A and B, in immune cells in rheumatoid arthritis in humans and mouse models. Arthritis Rheum. 65(7), 1725-1735 (2013).
60. Van Bavel CC, Dieker JW, Kroeze Y et al. Apoptosis-induced histone H3 methylation is targeted by autoantibodies in systemic lupus erythematosus. Ann. Rheum. Dis. 70(1), 201-207 (2011).
61. Zouali M. Epigenetics in lupus. Ann. NY Acad. Sci. 1217, 154-165 (2011).
62. Guo S, Liu Y, Ma Y et al. Systemic lupus erythematosus patients contain significantly less igm against mono-methylated lysine than healthy subjects. PLoS ONE 8(7), e68520 (2013).
63. Sokolove J, Bromberg R, Deane KD et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 7(5), e35296 (2012).
64. Darrah E, Rosen A, Giles JT, Andrade F. Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Ann. Rheum. Dis. 71(1), 92-98 (2012).
65. Auger I, Charpin C, Balandraud N, Martin M, Roudier J. Autoantibodies to PAD4 and BRAF in rheumatoid arthritis. Autoimmun. Rev. 11(11), 801-803 (2012).
66. Halvorsen EH, Pollmann S, Gilboe IM et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann. Rheum. Dis. 67(3), 414-417 (2008). (Pubitemid 351281280)
67. Pollmann S, Stensland M, Halvorsen EH et al. Anti-PAD4 autoantibodies in rheumatoid arthritis. levels in serum over time and impact on PAD4 activity as measured with a small synthetic substrate. Rheumatol. Int. 32(5), 1271-1276 (2012).
68. Zhao J, Zhao Y, He J, Jia R, Li Z. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J. Rheumatol. 35(6), 969-974 (2008). (Pubitemid 351813138)
69. Harris ML, Darrah E, Lam GK et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum. 58(7), 1958-1967 (2008). (Pubitemid 351988087)
70. Kolfenbach JR, Deane KD, Derber LA et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 62(9), 2633-2639 (2010).
71. Darrah E, Giles JT, Ols ML, Bull HG, Andrade F, Rosen A. Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci. Transl. Med. 5(186), 186-165 (2013).
72. Liu CL, Tangsombatvisit S, Rosenberg JM et al. Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Res. Ther. 14(1), R25 (2012).
73. Wang Y, Li M, Stadler S et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J. Cell Biol. 184(2), 205-213 (2009).
74. Leshner M, Wang S, Lewis C et al. PAD4 mediated histone hypercitrullination induces heterochromatin decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures. Front. Immunol. 3, 307 (2012).
75. Rohrbach AS, Slade DJ, Thompson PR, Mowen KA. Activation of PAD4 in NET formation. Front. Immunol. 3, 360 (2012).
76. Pratesi F, Dioni I, Tommasi C et al. Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202765 (2013) (Epub ahead of print).
77. Skene PJ, Henikoff S. Histone variants in pluripotency and disease. Development 140(12), 2513-2524 (2013).
78. Kurumizaka H, Horikoshi N, Tachiwana H, Kagawa W. Current progress on structural studies of nucleosomes containing histone H3 variants. Curr. Opin. Struct. Biol. 23(1), 109-115 (2013).
79. Hudson M, Mahler M, Pope J et al. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J. Rheumatol. 39(4), 787-794 (2012).
80. Russo K, Hoch S, Dima C, Varga J, Teodorescu M. Circulating anticentromere CENP-A and CENP-B antibodies in patients with diffuse and limited systemic sclerosis, systemic lupus erythematosus, and rheumatoid arthritis. J. Rheumatol. 27(1), 142-148 (2000). (Pubitemid 30058641)
81. Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 3(10), 1113-1121 (2013).
82. Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell 153(3), 516-519 (2013).
83. Gurtan AM, Sharp PA. The role of miRNAs in regulating gene expression networks. J. Mol. Biol. 425(19), 3582-3600 (2013).
84. Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK. MicroRNAs in systemic rheumatic diseases. Arthritis Res. Ther. 13(4), 229 (2011).
85. Hu R, O'connell RM. MicroRNA control in the development of systemic autoimmunity. Arthritis Res. Ther. 15(1), 202 (2013).
86. Dai R, Ahmed SA. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl. Res. 157(4), 163-179 (2011).
87. Goldring MB, Marcu KB. Epigenomic and microRNA-mediated regulation in cartilage development, homeostasis, and osteoarthritis. Trends Mol. Med. 18(2), 109-118 (2012).
88. Urdinguio RG, Fernandez AF, Lopez-Nieva P et al. Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome. Epigenetics 5(7), 656-663 (2010).
89. Miao CG, Yang YY, He X et al. New advances of microRNAs in the pathogenesis of rheumatoid arthritis, with a focus on the crosstalk between DNA methylation and the microRNA machinery. Cell. Signal. 25(5), 1118-1125 (2013).
90. Filková M, Aradi B, Šenolt L et al. Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202815 (2013) (Epub ahead of print).
91. Zhu S, Pan W, Song X et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat. Med. 18(7), 1077-1086 (2012).
92. Pauley KM, Stewart CM, Gauna AE et al. Altered miR-146a expression in Sjogren's syndrome and its functional role in innate immunity. Eur J. Immunol. 41(7), 2029-2039 (2011).
93. Hashemi M, Eskandari-Nasab E, Zakeri Z et al. Association of pre-miRNA-146a rs2910164 and premiRNA-499 rs3746444 polymorphisms and susceptibility to rheumatoid arthritis. Mol. Med. Rep. 7(1), 287-291 (2013).
94. Wang H, Peng W, Ouyang X, Li W, Dai Y. Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl. Res. 160(3), 198-206 (2012).
95. Zhao S, Wang Y, Liang Y et al. MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1. Arthritis Rheum. 63(5), 1376-1386 (2011).
96. Pan W, Zhu S, Yuan M et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J. Immunol. 184(12), 6773-6781 (2010).
97. Qin H, Zhu X, Liang J et al. MicroRNA-29b contributes to DNA hypomethylation of CD4+ T cells in systemic lupus erythematosus by indirectly targeting DNA methyltransferase 1. J. Dermatol. Sci. 69(1), 61-67 (2013).
98. Carlsen AL, Schetter AJ, Nielsen CT et al. Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum. 65(5), 1324-1334 (2013).
99. Zhang H, Zhao M, Lv Z et al. MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell. Physiol. Biochem. 31(1), 56-65 (2013).
100. Qiu S, Huang D, Yin D et al. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochim. Biophys. Acta 1832(10), 1697-1707 (2013).
101. Guan YJ, Yang X, Wei L, Chen Q. MiR-365: a mechanosensitive microRNA stimulates chondrocyte differentiation through targeting histone deacetylase 4. FASEB J. 25(12), 4457-4466 (2011).
102. Tuddenham L, Wheeler G, Ntounia-Fousara S et al. The cartilage specific microRNA-140 targets histone deacetylase 4 in mouse cells. FEBS Lett. 580(17), 4214-4217 (2006). (Pubitemid 44037596)
103. Li Z, Hassan MQ, Jafferji M et al. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J. Biol. Chem. 284(23), 15676-15684 (2009).
104. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J. Biol. Chem. 286(29), 25992-26002 (2011).
105. Shakibaei M, Shayan P, Busch F et al. Resveratrol mediated modulation of Sirt-1/Runx2 promotes osteogenic differentiation of mesenchymal stem cells. potential role of Runx2 deacetylation. PLoS ONE 7(4), e35712 (2012).
106. Wang G, Tam LS, Li EK et al. Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus 20(5), 493-500 (2011).
107. Hu N, Long H, Zhao M, Yin H, Lu Q. Aberrant expression pattern of histone acetylation modifiers and mitigation of lupus by SIRT1-siRNA in MRL/lpr mice. Scand. J. Rheumatol. 38(6), 464-471 (2009).
108. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 42(1), 609-621 (2013).
109. Janssen HL, Reesink HW, Lawitz EJ et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368(18), 1685-1694 (2013).
110. Reilly CM, Mishra N, Miller JM et al. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. J. Immunol. 173(6), 4171-4178 (2004). (Pubitemid 39280783)
111. Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111(4), 539-552 (2003). (Pubitemid 36228011)
112. Garcia BA, Busby SA, Shabanowitz J, Hunt DF, Mishra N. Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. J. Proteome Res. 4(6), 2032-2042 (2005). (Pubitemid 41814269)
113. Grabiec AM, Tak PP, Reedquist KA. Function of histone deacetylase inhibitors in inflammation. Crit. Rev. Immunol. 31(3), 233-263 (2011).
114. Grabiec AM, Reedquist KA. The ascent of acetylation in the epigenetics of rheumatoid arthritis. Nat. Rev. Rheumatol. 9(5), 311-318 (2013).
115. Saouaf SJ, Li B, Zhang G et al. Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87(2), 99-104 (2009).
116. Kristensen LH, Nielsen AL, Helgstrand C et al. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2, 4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor. FEBS J. 279(11), 1905-1914 (2012).
117. Nakagawa-Yagi Y, Sato Y, Matsumoto E et al. Pharmacological modulation of histone demethylase activity by a small molecule isolated from subcritical water extracts of Sasa senanensis leaves prolongs the lifespan of Drosophila melanogaster. BMC Complement. Altern. Med. 12, 101 (2012).
118. Kruidenier L, Chung CW, Cheng Z et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488(7411), 404-408 (2012).
119. Jones JE, Slack JL, Fang P et al. Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors. ACS Chem. Biol. 7(1), 160-165 (2012).
120. Slack JL, Causey CP, Thompson PR. Protein arginine deiminase 4: a target for an epigenetic cancer therapy. Cell. Mol. Life Sci. 68(4), 709-720 (2011).
121. Wang Y, Li P, Wang S et al. Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity. J. Biol. Chem. 287(31), 25941-25953 (2012).
122. Dreyton CJ, Jones JE, Knuckley BA et al. Optimization and characterization of a pan protein arginine deiminase (PAD) inhibitor. In: Probe Reports from the NIH Molecular Libraries Program. National Center for Biotechnology Information (US) (Ed.). Bethesda, MD, USA (2010).
123. Knuckley B, Causey CP, Jones JE et al. Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3. Biochemistry 49(23), 4852-4863 (2010).
124. Bozdag M, Dreker T, Henry C et al. Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors. Bioorg. Med. Chem. Lett. 23(3), 715-719 (2013).
125. Lin NY, Beyer C, Giessl A et al. Autophagy regulates TNFalpha-mediated joint destruction in experimental arthritis. Ann. Rheum. Dis. 72(5), 761-768 (2013).
126. Knight JS, Zhao W, Luo W et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J. Clin. Invest. 123(7), 2981-2993 (2013).
127. Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res. 73(2), 473-477 (2013).
128. Lopez-Serra P, Esteller M. DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 31(13), 1609-1622 (2012).
129. Jiang M, Xiang Y, Wang D et al. Dysregulated expression of miR-146a contributes to age-related dysfunction of macrophages. Aging Cell 11(1), 29-40 (2012).
130. Hu R, Wallace J, Dahlem TJ, Grunwald DJ, O'connell RM. Targeting human microRNA genes using engineered Tal-effector nucleases (TALENs). PLoS ONE 8(5), e63074 (2013).
131. Baird AM, Gray SG, O'Byrne KJ. Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. PLoS ONE 6(1), e14593 (2011).
132. Baird AM, Gray SG, O'Byrne KJ. IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. Eur. J. Cancer 47(12), 1908-1918 (2011).
133. Hofmann SR, Rosen-Wolff A, Tsokos GC, Hedrich CM. Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin. Immunol. 143(2), 116-127 (2012).
134. Rauen T, Hedrich CM, Juang YT, Tenbrock K, Tsokos GC. cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. J. Biol. Chem. 286(50), 43437-43446 (2011).
135. Croxford AL, Mair F, Becher B. IL-23: one cytokine in control of autoimmunity. Eur J. Immunol. 42(9), 2263-2273 (2012).
136. Guo YY, Wang NZ, Zhao S, Hou LX, Xu YB, Zhang N. Increased interleukin-23 is associated with increased disease activity in patients with rheumatoid arthritis. Chin. Med. J. (Engl.) 126(5), 850-854 (2013).
137. Kim HR, Cho ML, Kim KW et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB-and p38 MAPK-dependent signaling pathways. Rheumatology (Oxford) 46(1), 57-64 (2007).
138. Kim J, Kang S, Kwon G, Koo S. Elevated levels of T helper 17 cells are associated with disease activity in patients with rheumatoid arthritis. Ann. Lab. Med. 33(1), 52-59 (2013).
139. Kyttaris VC, Kampagianni O, Tsokos GC. Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice. Biomed. Res. Int. 861028 (2013).
140. Baird AM, Leonard J, Naicker KM, Kilmartin L, O'byrne KJ, Gray SG. IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Lung Cancer 79(1), 83-90 (2013).
141. Cathcart MC, Gray SG, Baird AM et al. Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer. Cancer 117(22), 5121-5132 (2011).
142. Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann. Rheum. Dis. 71(3), 424-431 (2012).
143. Quddus J, Johnson KJ, Gavalchin J et al. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J. Clin. Invest. 92(1), 38-53 (1993). (Pubitemid 23208979)
144. Vojinovic J, Damjanov N, D'urzo C et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63(5), 1452-1458 (2011).
145. Laitinen K, Gylling H. Dose-dependent LDL-cholesterol lowering effect by plant stanol ester consumption: clinical evidence. Lipids Health Dis. 11, 140 (2012).
146. Link A, Balaguer F, Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol 80(12), 1771-1792 (2010).
147. Cuevas A, Saavedra N, Salazar LA, Abdalla DS. Modulation of immune function by polyphenols: possible contribution of epigenetic factors. Nutrients 5(7), 2314-2332 (2013).
148. Lawless MW, O'byrne KJ, Gray SG. Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. J. Cell. Mol. Med. 13(9A), 2800-2821 (2009).
149. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother. Res. 26(11), 1719-1725 (2012).
150. Lee H, Kim H, Lee G, Chung HS, Bae H. Curcumin attenuates lupus nephritis upon interaction with regulatory T cells in New Zealand black/white mice. Br. J. Nutr. 110(1), 69-76 (2013).
151. Bao B, Ali S, Banerjee S et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res. 72(1), 335-345 (2012).
152. Foxley S, Zamora M, Hack B et al. Curcumin aggravates CNS pathology in experimental systemic lupus erythematosus. Brain Res. 1504, 85-96 (2013).
153. Thomasset S, Teller N, Cai H et al. Do anthocyanins and anthocyanidins, cancer chemopreventive pigments in the diet, merit development as potential drugs? Cancer Chemother. Pharmacol. 64(1), 201-211 (2009).
154. Seong AR, Yoo JY, Choi K et al. Delphinidin, a specific inhibitor of histone acetyltransferase, suppresses inflammatory signaling via prevention of NF-kappaB acetylation in fibroblast-like synoviocyte MH7A cells. Biochem. Biophys. Res. Commun. 410(3), 581-586 (2011).
155. Hafeez BB, Siddiqui IA, Asim M et al. A dietary anthocyanidin delphinidin induces apoptosis of human prostate cancer PC3 cells in vitro and in vivo. involvement of nuclear factor-kappaB signaling. Cancer Res. 68(20), 8564-8572 (2008).
156. Beher D, Wu J, Cumine S et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 74(6), 619-624 (2009).
157. Hubbard BP, Gomes AP, Dai H et al. Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science 339(6124), 1216-1219 (2013).
158. Park SJ, Ahmad F, Philp A et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 148(3), 421-433 (2012).
159. Venturelli S, Berger A, Bocker A et al. Resveratrol as a Pan-HDAC inhibitor alters the acetylation status of histone proteins in human-derived hepatoblastoma cells. PLoS ONE 8(8), e73097 (2013).
160. Byun HS, Song JK, Kim YR et al. Caspase-8 has an essential role in resveratrol-induced apoptosis of rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford) 47(3), 301-308 (2008). (Pubitemid 351267195)
161. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 30(1-2), 1-6 (2007). (Pubitemid 46438042)
162. Glehr M, Fritsch-Breisach M, Lohberger B et al. Influence of resveratrol on rheumatoid fibroblast-like synoviocytes analysed with gene chip transcription. Phytomedicine 20(3-4), 310-318 (2013).
163. Nakayama H, Yaguchi T, Yoshiya S, Nishizaki T. Resveratrol induces apoptosis MH7A human rheumatoid arthritis synovial cells in a sirtuin 1-dependent manner. Rheumatol. Int. 32(1), 151-157 (2012).
164. Tian J, Chen JW, Gao JS, Li L, Xie X. Resveratrol inhibits TNF-alpha-induced IL-1beta, MMP-3 production in human rheumatoid arthritis fibroblast-like synoviocytes via modulation of PI3kinase/Akt pathway. Rheumatol. Int. 33(7), 1829-1835 (2013).
165. Gerhauser C. Epigenetic impact of dietary isothiocyanates in cancer chemoprevention. Curr. Opin. Clin. Nutr. Metab. Care 16(4), 405-410 (2013).
166. Clarke JD, Riedl K, Bella D, Schwartz SJ, Stevens JF, Ho E. Comparison of isothiocyanate metabolite levels and histone deacetylase activity in human subjects consuming broccoli sprouts or broccoli supplement. J. Agric. Food Chem. 59(20), 10955-10963 (2011).
167. Park JH, Kim JW, Lee CM et al. Sulforaphane inhibits the Th2 immune response in ovalbumin-induced asthma. BMB Rep. 45(5), 311-316 (2012).
168. Kong JS, Yoo SA, Kim HS et al. Inhibition of synovial hyperplasia, rheumatoid T cell activation, and experimental arthritis in mice by sulforaphane, a naturally occurring isothiocyanate. Arthritis Rheum. 62(1), 159-170 (2010).
169. James D, Devaraj S, Bellur P, Lakkanna S, Vicini J, Boddupalli S. Novel concepts of broccoli sulforaphanes and disease: induction of phase II antioxidant and detoxification enzymes by enhanced-glucoraphanin broccoli. Nutr. Rev. 70(11), 654-665 (2012).
170. Christiansen B, Bellostas Muguerza N, Petersen AM et al. Ingestion of broccoli sprouts does not improve endothelial function in humans with hypertension. PLoS ONE 5(8), e12461 (2010).
171. Armah CN, Traka MH, Dainty JR et al. A diet rich in high-glucoraphanin broccoli interacts with genotype to reduce discordance in plasma metabolite profiles by modulating mitochondrial function. Am. J. Clin. Nutr. 98(3), 712-722 (2013).
172. Yang ML, Gee AJ, Gee RJ et al. Lupus autoimmunity altered by cellular methylation metabolism. Autoimmunity 46(1), 21-31 (2013).
173. Strickland FM, Hewagama A, Wu A et al. Diet influences expression of autoimmune-associated genes and disease severity by epigenetic mechanisms in a transgenic mouse model of lupus. Arthritis Rheum. 65(7), 1872-1881 (2013).
174. Ha MK, Song YH, Jeong SJ et al. Emodin inhibits proinflammatory responses and inactivates histone deacetylase 1 in hypoxic rheumatoid synoviocytes. Biol. Pharm. Bull. 34(9), 1432-1437 (2011).
175. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci. Transl. Med. 4(127), 127ps110 (2012).
176. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 72(19), 4875-4882 (2012).
177. You S, Cho CS, Lee I, Hood L, Hwang D, Kim WU. A systems approach to rheumatoid arthritis. PLoS ONE 7(12), e51508 (2012).
178. The Structural Genomics Consortium. www.thesgc.org/epigenetics
179. Davidson RK, Jupp O, De Ferrars R et al. Sulforaphane represses matrix-degrading proteases and protects cartilage from destruction in vitro and in vivo. Arthritis Rheum. 65(12), 3130 (2013).